MSB 5.24% $1.11 mesoblast limited

banter and General Discussion, page-9517

  1. 605 Posts.
    lightbulb Created with Sketch. 307
    yes quartery incoming. dont expect it to be too "hawkish"

    something like this.

    financials
    -placement completed
    -cash burn
    -royalties on temcell.

    operations
    -orphan drug and rare disease designation for hlhs.
    plan to meet fda to discuss possibility of the trial supporting accelerated approval.
    -accelerated approval pathway supported for lvad.
    plan to meet fda pre bla submission.
    -gvhd data sufficient to refile. intend to refile current quarter.
    -backpain trial underway.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.